We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Study Reveals Immune Mechanism Driving Severe COVID-19 Progression

By LabMedica International staff writers
Posted on 26 Jul 2026

Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. More...

Type I interferons are central to host defense, yet their failure in critical illness has been difficult to explain. Clarifying this mechanism could guide risk assessment for viral infections that continue to burden health systems. New findings demonstrate how pre-existing immune factors can disable type I interferon activity in people who developed severe COVID-19.

At the University of Sharjah, investigators and international collaborators found that an affinity-matured autoimmune B‑cell response generates antibodies capable of neutralizing type I interferons. Under normal conditions, these cytokines alert neighboring cells and initiate antiviral programs; however, the study shows that in a subset of patients, the antibodies target interferon‑α and interferon‑ω and block their function. The work identifies three principal B‑cell epitopes spanning all major regions of type I interferons, explaining the breadth of neutralization.

The team combined patient‑derived monoclonal antibodies with X‑ray crystallography and AlphaFold3‑based structural analyses to map antibody–interferon interactions in detail. Extensive somatic hypermutation and evidence of prolonged affinity maturation were observed, indicating a mature, organized autoimmune response rather than a transient byproduct of severe infection. Researchers examined hundreds of antibodies, revealing how this response can exist silently prior to viral exposure and then undermine innate defenses at infection onset.

According to the authors, the findings help explain why some individuals progressed to life‑threatening disease during SARS‑CoV‑2 infection and may be relevant to other respiratory viruses, including seasonal influenza. The study is global in scope, with contributors from universities and research institutes across France, Switzerland, Canada, Spain, Belgium, Saudi Arabia, Sweden, Denmark, Italy, the U.S., Estonia, and the United Arab Emirates. The work was published in Cell.

“The researchers found that these patients had a large and diverse population of B cells specifically programmed to recognize interferons,” said Rabih Halwani, professor of immunology at the University of Sharjah. “Importantly, this abnormal immune response was detectable before the patients developed life-threatening viral disease, suggesting that it was not simply a consequence of severe infection but rather a pre-existing defect that may have contributed to the patients' vulnerability.”

Related Links
University of Sharjah


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: LVOne uses blood-based biomarkers to detect stroke and identify large vessel occlusion before hospital arrival, providing objective results earlier than traditional assessments. (Photo courtesy of UpFront Diagnostics)

First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage

Rapid stroke identification before hospital arrival is critical because treatment efficacy declines with every minute of delay. However, definitive assessment typically requires hospital-based imaging,... Read more

Molecular Diagnostics

view channel
Image: The proposed workflow adds liquid biopsy to detect genetic and molecular signs of cancer in CSF samples already collected during autoimmune encephalitis evaluation. (Image Credit: Shutterstock)

CSF Liquid Biopsy Could Help Distinguish Cancer from Autoimmune Brain Inflammation

Autoimmune encephalitis can cause memory and behavioral changes, seizures, and altered consciousness, but diagnosis can be challenging because cancers involving the brain and central nervous system may... Read more

Microbiology

view channel
Image: Ebola remains a rapidly evolving public health threat with high mortality, underscoring the need for timely diagnosis and decentralized testing closer to patients (Image Credit: Adobe Stock)

Collaboration Targets Blood-Based Ebola Detection Outside Central Laboratories

Co-Diagnostics, Inc. (Salt Lake City, UT, USA) and ReadyGo Diagnostics Ltd. (Bath, UK) have initiated a collaboration to evaluate ReadyGo’s GoCollect with the Co-Dx PCR platform for blood-based molecular... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Collaboration combines cognitive assessment, blood testing, phlebotomy, and MRI to support faster diagnosis across the UK (Image Credt: Adobe Stock)

New UK Collaboration Expands Access to Integrated Alzheimer’s Diagnostic Testing

C2N Diagnostics and Cambridge Cognition have partnered with The Alzheimer’s Trust to create an integrated pathway aimed at supporting earlier and more accurate diagnosis of Alzheimer’s disease and related dementias.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.